Catabasis Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CATB research report →
About the company
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic treatments primarily within the United States. Their leading experimental drug, edasalonexent, is an oral small molecule undergoing Phase III clinical trials for Duchenne Muscular Dystrophy (DMD), functioning by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells.
- CEO
- Jill Milne
- IPO
- 2015
- Employees
- 20
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $234.86M
- P/E
- 0.00
- P/S
- 332.66
- P/B
- 0.00
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -15144.33%
- Net Margin
- -13938.24%
- ROE
- -37.70%
- ROIC
- -42.81%
- Revenue
- $0 · 0.00%
- Net Income
- $-94,260,000 · 0.00%
- EPS
- $-1.68 · 0.00%
- Op Income
- $-111,558,000
- FCF YoY
- 0.00%
- 52W High
- $10.26
- 52W Low
- $1.25
- 50D MA
- $8.23
- 200D MA
- $3.74
- Beta
- 1.66
- Avg Volume
- 528.92K
Get TickerSpark's AI analysis on CATB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 21 | Harshbarger Benjamin | other | 200,000 |
| Jun 2, 21 | Callori Fred | other | 85,000 |
| Jun 2, 21 | Violin Jonathan | other | 85,000 |
| Jun 2, 21 | Clauser Noah | other | 600,000 |
| Jun 2, 21 | KISHBAUCH MICHAEL D | other | 100,000 |
| Jun 2, 21 | BATE KENNETH | other | 100,000 |
| Jun 2, 21 | Milne Jill C. | other | 1,400,000 |
| Jun 2, 21 | LAPOINTE ANTHONY GREGG | other | 100,000 |
| Jun 2, 21 | Harshbarger Benjamin | other | 400,000 |
| Feb 1, 21 | PERCEPTIVE ADVISORS LLC | other | 1,617 |
Our CATB coverage
Recent articles, reports, and earnings notes.
No research on CATB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CATB report →Similar companies
Peers in the same neighborhood.